Literature DB >> 19451415

Phase II trials in journal of clinical oncology.

Stephen A Cannistra.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19451415     DOI： 10.1200/JCO.2009.23.1811

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  33 in total

1.  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Authors:  Hedy L Kindler; Theodore G Karrison; David R Gandara; Charles Lu; Lee M Krug; James P Stevenson; Pasi A Jänne; David I Quinn; Marianna N Koczywas; Julie R Brahmer; Kathy S Albain; David A Taber; Samuel G Armato; Nicholas J Vogelzang; Helen X Chen; Walter M Stadler; Everett E Vokes
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Authors:  Kenichiro Enooku; Ryosuke Tateishi; Fumihiko Kanai; Yuji Kondo; Ryota Masuzaki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-09-21       Impact factor: 7.527

3.  Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Authors:  Jennifer A Chan; Keith Stuart; Craig C Earle; Jeffrey W Clark; Pankaj Bhargava; Rebecca Miksad; Lawrence Blaszkowsky; Peter C Enzinger; Jeffrey A Meyerhardt; Hui Zheng; Charles S Fuchs; Matthew H Kulke
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

4.  Resampling phase III data to assess phase II trial designs and endpoints.

Authors:  Manish R Sharma; Theodore G Karrison; Yuyan Jin; Robert R Bies; Michael L Maitland; Walter M Stadler; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-01-27       Impact factor: 12.531

5.  Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Authors:  Manish A Shah; Minaxi Jhawer; David H Ilson; Robert A Lefkowitz; Edric Robinson; Marinela Capanu; David P Kelsen
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

6.  Establishing a Clinically Relevant Large Animal Model Platform for TBI Therapy Development: Using Cyclosporin A as a Case Study.

Authors:  Susan S Margulies; Todd Kilbaugh; Sarah Sullivan; Colin Smith; Kathleen Propert; Melissa Byro; Kristen Saliga; Beth A Costine; Ann-Christine Duhaime
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

7.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Authors:  Harriet M Kluger; Veronica Chiang; Amit Mahajan; Christopher R Zito; Mario Sznol; Thuy Tran; Sarah A Weiss; Justine V Cohen; James Yu; Upendra Hegde; Elizabeth Perrotti; Gail Anderson; Amanda Ralabate; Yuval Kluger; Wei Wei; Sarah B Goldberg; Lucia B Jilaveanu
Journal:  J Clin Oncol       Date:  2018-11-08       Impact factor: 44.544

Review 8.  Randomized phase II trials: a long-term investment with promising returns.

Authors:  Manish R Sharma; Walter M Stadler; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2011-06-27       Impact factor: 13.506

9.  Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care.

Authors:  N Penel; S Clisant; E Dansin; C Desauw; M Dégardin; L Mortier; M Vanhuyse; F Bonodeau; C Fournier; J-L Cazin; A Adenis
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

10.  Melanoma: a model for testing new agents in combination therapies.

Authors:  Paolo A Ascierto; Howard Z Streicher; Mario Sznol
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.